Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
CSF IL-8 In Acute And Chronic Inflammatory Polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
CSF IL-8 In Acute And Chronic Inflammatory Polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
CSF IL-8 In Acute And Chronic Inflammatory Polyneuropathies
Ivan Kmezic
Abstract
Discussion Forum (0)
CSF IL-8 In Acute And Chronic Inflammatory Polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
CSF IL-8 In Acute And Chronic Inflammatory Polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
Poster No: 1136
Presenter: Ivan Kmezic
Institution: Karolinska Institutet, Department of Clinical Neuroscience
Introduction: There is a lack of reliable biomarkers for acute and chronic inflammatory polyneuropathies. Interleukin-8 (IL-8) is released by activated macrophages and acts as a neutrophil chemoattractant. Our pilot proteomics study revealed high levels of IL-8 in cerebrospinal fluid (CSF), but not in plasma in a small GBS cohort. To further investigate the roll of IL-8 in inflammatory polyneuropathies we preformed this study.
Methods: Study population: Guillain-Barré syndrome (GBS, n=26), chronic inflammatory demyelinating polyneuropathy (CIDP, n=23), paraproteinemia-related demyelinating polyneuropathy (PDN, n=6), multifocal motor neuropathy (MMN, n=6), healthy controls (HC, n=44), non-inflammatory polyneuropathies (NIP, n=29), multiple sclerosis (MS, n=33), amyotrophic lateral sclerosis (ALS, n=31). Study design: retrospective cohort study. CSF was analyzed with ELISA method prior to and following immunomodulatory treatment.
Results: 1] IL-8 levels in GBS were higher compared to all subtypes of chronic inflammatory polyneuropathies (CIDP, PDN, MMN), and all control groups. 2] IL-8 levels in CIDP and PDN were higher compared to HC. 3] Post-treatment levels of IL-8 in GBS were lower than pre-treatment levels. However, in CIDP, post-treatment IL-8 levels remained as high as pre-treatment levels, and also higher compared to that in HC. 4] IL-8 levels correlated with impairment in GBS 0-12 months after diagnosis and at 18 months in CIDP.
Conclusions: CSF IL-8 could be used as a diagnostic biomarker in patients with GBS, CIDP, and PDN, and a prognostic biomarker in patients with GBS and CIDP. Cerebrospinal IL-8 activation seems to be specific to immune-mediated polyneuropathies, but not immune-mediated disorders of the central nervous system, i.e., MS. IL-8 levels in the CSF reduce after immunomodulatory treatment in GBS. Further studies: Further investigation of IL-8 signaling pathways and it´s role in the pathogenesis of inflammatory polyneuropathies is called for.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: biomarker, interleukin-8, inflammatory polyneuropathies
{{ help_message }}
{{filter}}